TOP TEN perturbations for 38666_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38666_at
Selected probe(set): 202880_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38666_at (202880_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

FoxO3 H212R overexpr. study 1 / transfected HUVEC sample (FoxO3)

Relative Expression (log2-ratio):2.6872063
Number of Samples:3 / 3
Experimental FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control transfected HUVEC sample (FoxO3)
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, without 4OHT. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, and harvested after 12 hours for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments.

4-hydroxytamoxifen study 1 (empty vector) / FoxO3 H212R overexpr. study 1

Relative Expression (log2-ratio):-2.5385761
Number of Samples:3 / 3
Experimental 4-hydroxytamoxifen study 1 (empty vector)
Human umbilical vein endothelial cells (HUVECs) transfected with empty retroviral pBabe puro vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):-2.358512
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.2061653
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-2.1791325
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

TGF-ß study 5 (late) / untreated A549 cell sample

Relative Expression (log2-ratio):2.1367989
Number of Samples:3 / 3
Experimental TGF-ß study 5 (late)
Human A549 cells were treated with 5ng/ml porcine TGF-ß after serum-starving for 24h. Samples were taken 72 hours after TGF-ß treatment.
Control untreated A549 cell sample
A549 cells were grown for 24 hours. Samples were taken immediately before TGF-ß treatment.

FoxO3 H212R overexpr. study 1 / transfected HUVEC sample (mutated FoxO3 H212R)

Relative Expression (log2-ratio):2.107603
Number of Samples:3 / 3
Experimental FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control transfected HUVEC sample (mutated FoxO3 H212R)
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), without 4OHT. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, and harvested after 12 hours for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments.

TNF-ɑ study 20 / normal monocyte sample

Relative Expression (log2-ratio):1.9255581
Number of Samples:3 / 7
Experimental TNF-ɑ study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling.
Control normal monocyte sample
Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.

TGF-ß study 5 (intermediate) / untreated A549 cell sample

Relative Expression (log2-ratio):1.9222488
Number of Samples:9 / 3
Experimental TGF-ß study 5 (intermediate)
Human A549 cells were treated with 5ng/ml porcine TGF-ß after serum-starving for 24h. Samples were taken 8, 16, 24 hours after TGF-ß treatment.
Control untreated A549 cell sample
A549 cells were grown for 24 hours. Samples were taken immediately before TGF-ß treatment.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):-1.8734465
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.